Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemvaleukin alfa + Pembrolizumab in HNSCC
NCT04144517Phase 2Completed
- Sponsor
- Mural Oncology
- Start
- Feb 2020
- Primary completion
- Oct 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of nemvaleukin alfa in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Mural Oncology. Primary endpoint: Overall Response Rate up to 49 weeks. Started Feb 2020; status: completed.
02
Drugs
nemvaleukin alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04144517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144517.